StockIQpro
NASDAQ:TELA

TELA Bio, Inc.

Track all markets on TradingView
Track all markets on TradingView

TELA Bio, Inc.'s revenue grew 15.8% in fiscal 2025 to $80.3M while operating margin rose to −42.0%, its highest in 9 years. Free cash flow was −$28.7M, −35.7% of revenue, and the diluted share count rose 64.6%.Summary generated from TELA Bio, Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$80.3M
Revenue growth+15.8%
Revenue, 5-yr CAGR+34.5%
Gross margin67.7%
Operating margin−42.0%
Net margin−48.4%
ROIC−190.3%
Return on equity−223.4%
Debt / equity8.82
Free cash flow−$28.7M
FCF margin−35.7%
Share count change+64.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue2941586980
Operating income−29−39−44−34−34
Net income−33−44−47−38−39
Free cash flow−31−42−41−43−29

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus